Navigation Links
Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
Date:7/16/2009

cquisitions; and any other factors that may affect performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this press release to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the continued availability of capital to finance our activities; and any other factors referenced in our other filings with the Securities and Exchange Commission ("SEC") and applicable Canadian regulatory authorities. For a more thorough discussion of the risks associated with our business, see the "Risk Factors" section in our annual report for the year ended December 31, 2008 filed with the SEC on Form 10-K, and our quarterly report for the three months ended March 31, 2009 filed with the SEC on Form 10-Q.

Given these uncertainties, assumptions and risk factors, readers are cautioned not to place undue reliance on such forward-looking statements. Except as required by law, we disclaim any obligation to update any such factors
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces conference call and webcast
2. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
3. Angiotech Enters License, Distribution and Supply Agreements for Fibrin and Thrombin Technologies with Haemacure Corporation
4. Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
5. Angiotechs corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent
6. Angiotech launches e-commerce website that allows customers to order Quill(TM) SRS product line
7. Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
8. Angiotech announces date of annual general meeting of shareholders
9. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
10. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
11. Angiotech announces positive results from Bio-Seal(TM) clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... (PRWEB) September 30, 2014 ... solutions for drug discovery and related life ... consortium has chosen Genedata Selector as its ... (NGS) data. FUNGITECT is a European consortium ... fungal diseases via individualized anti-fungal drug therapies. ...
(Date:9/30/2014)... CORALVILLE, Iowa , Sept. 30, 2014 /PRNewswire/ ... in the discovery and development of proprietary new ... United States Patent and Trademark Office (USPTO) issued ... patent application entitled, "Benzoic Acid, Benzoic Acid Derivatives ... Methods of Making and Use Thereof." ...
(Date:9/30/2014)... MAR, Calif. , Sept. 30, 2014 ... for women,s health announces its receipt of a patent ... FemmyCycle menstrual cup has also received FDA clearance in ... Canada, and the CE in Europe. This patent is related ... conjunction with this issuance, the company is releasing FemmyCycle ...
(Date:9/30/2014)... LONDON , Sept. 30, 2014 ... analyze global next-generation (NGS) sequencing trends and use. ... technology use is expected to increase within the ... are the top criteria for purchasing sequencing instruments. ... technologies. The popularity of RNA-Seq continues to surge, ...
Breaking Biology Technology:FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2The FemmyCycle 2Global Next-generation Sequencing Trends 2
... ATLANTA, Nov. 6, 2010 Alder Biopharmaceuticals Inc. today announced ... antibody therapeutic will be presented at the Annual Meeting of ... continue to be encouraged about the clinical data from the ... for the first time, from our Phase 1 study of ...
... Inc. (Nasdaq: CLRT ) announced today that its ... stockholders tender their shares to General Electric Company (NYSE: ... per share of Clarient,s common stock and $20.00 per share ... transaction is expected to close during the fourth quarter of ...
... CAMBRIDGE, Mass., Nov. 5, 2010 Metamark Genetics, Inc., ... the appointment of Mark R. Straley as the company,s ... Board of Directors. Kenneth E. Weg, a Metamark co-founder ... serve as Chairman of the Board of Directors. ...
Cached Biology Technology:Alder Biopharmaceuticals Announces That Data From Multiple Studies of ALD518 (BMS945429), an Investigational Antibody Therapeutic in Rheumatoid Arthritis Patients, to be Presented at Annual Meeting of the American College of Rheumatology 2Clarient's Board of Directors Recommends Stockholders Accept General Electric's Cash Tender Offer 2Clarient's Board of Directors Recommends Stockholders Accept General Electric's Cash Tender Offer 3Clarient's Board of Directors Recommends Stockholders Accept General Electric's Cash Tender Offer 4Metamark Genetics, Inc. Announces New Chief Executive Officer 2
(Date:9/29/2014)... culture, mathematics is often deemed inaccessible or esoteric. Yet ... important role in our daily lives and a decisive ... often behind the scenes. , UC Santa Barbara,s ... and an assistant professor of mechanical engineering, often works ... his recent research published in the Proceedings of ...
(Date:9/29/2014)... of dinosaurs, gigantic reptilesdistant relatives of modern crocodilesruled the ... and it was thought they didn,t much interact. But ... researcher in the thigh of one of these ancient ... an earth and planetary sciences lecturer, and her Virginia ... bite marks in the thigh bones of an old ...
(Date:9/29/2014)... , Canda, September 29, 2014 ... as UID Coupled with Increasing Security Concerns Continue ... India is one of ... increasing adoption of biometrics systems, majorly in various ... NREGA, etc. Fingerprint modality based biometrics dominates the ...
Breaking Biology News(10 mins):At the interface of math and science 2At the interface of math and science 3At the interface of math and science 4Tooth serves as evidence of 220 million-year-old attack 2India Biometrics Market to Surpass USD2.7 Billion by 2019, Finds TechSci Research Study 2India Biometrics Market to Surpass USD2.7 Billion by 2019, Finds TechSci Research Study 3
... Through a collaborative genome-wide study on individuals, researchers ... with heart rate. Since heart rate is a ... better understanding of genetic regulation of heart beat and ... drugs to treat cardiovascular disease. The study, titled, ...
... can keep clogged leg arteries open, preventing amputation ... the Society of Interventional Radiology,s 38th Annual Scientific ... (or PAD) is becoming increasingly prevalent due to ... epidemics," said Robert A. Lookstein, M.D., FSIR, lead ...
... WEST ORANGE, N.J.The State of Spinal Cord Injury: Latest ... Recovery will be held on Wednesday, April 17, 2013, ... Pleasant Valley Way, West Orange, N.J. This special Grand ... Cord Injury System (NNJSCIS) and the Spinal Cord Injury ...
Cached Biology News:Mount Sinai study identifies new gene variations associated with heart rate 2Drug-coated stents prevent leg amputation 2The State of Spinal Cord Injury Grand Rounds 2
Prepared from plasminogen by activation with immobilized human uPA...
(3-[125I]iodotyrosyl26)Galanin (porcine), 925 kBq, 25 uCi. Category: IODINE LIGANDS....
Immunogen: Synthetic Peptide: V(22) N G H E F E I E G E G E G R(36) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Mouse Endoglin/CD105 Fluorescein MAb (Clone 209701)...
Biology Products: